BCYC NASDAQ
Bicycle Therapeutics plc
1W: -8.4%
1M: -21.4%
3M: -22.3%
YTD: -49.4%
1Y: -59.4%
3Y: -83.4%
5Y: -92.1%
$3.38
-0.18 (-5.06%)
Weekly Expected Move ±5.9%
$3
$3
$3
$4
$4
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$73M
+105.8% ▲
5Y CAGR: +47.5%
Gross Profit
$73M
+152.7% ▲
Operating Income
-$247M
-17.7% ▼
Net Income
-$219M
-29.5% ▼
EPS (Diluted)
$-3.16
-9.0% ▼
EBITDA
-$277M
-67.9% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $12M | $14M | $27M | $35M | $73M |
| YoY Growth | +12.6% | +23.6% | +86.5% | +30.8% | +105.8% |
| Cost of Revenue | $0 | $0 | $156M | $173M | $6M |
| Gross Profit | $12M | $14M | -$130M | -$138M | $73M |
| Gross Margin | 100.0% | 100.0% | -480.1% | -390.3% | 100.0% |
| R&D Expenses | $45M | $82M | $156M | $173M | $240M |
| SG&A Expenses | $32M | $50M | $60M | $71M | $79M |
| Operating Expenses | $77M | $131M | $60M | $72M | $350M |
| Operating Income | -$66M | -$117M | -$190M | -$210M | -$247M |
| Operating Margin | -561.0% | -806.6% | -704.1% | -595.0% | -340.4% |
| Interest Expense | $3M | $3M | $3M | $2M | $206K |
| Income Before Tax | -$68M | -$114M | -$179M | -$174M | -$254M |
| Tax Expense | -$2M | -$2M | $1M | -$5M | $152K |
| Net Income | -$67M | -$113M | -$181M | -$169M | -$219M |
| Net Margin | -571.2% | -779.3% | -669.7% | -479.2% | -301.7% |
| EPS (Diluted) | $-2.67 | $-3.80 | $-5.08 | $-2.90 | $-3.16 |
| EBITDA | -$64M | -$107M | -$183M | -$165M | -$277M |
| Shares Outstanding | 25M | 30M | 36M | 58M | 69M |